Search research articles
Contact Us
Filters
Showing results (21-30 of 209) with videos related to
Page
of 21
Sort By:
Current Oncology (Toronto, Ont.)
|
November 26, 2025
Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review
Hervé Bischoff, Sébastien Gendarme, Laura Somme, et al.
Journal of Medical Economics
|
December 2, 2024
The impact of <i>KRAS</i> mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany
Christos Chouaid, Andromachi Giannopoulou, Alexandra Starry, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
March 30, 2004
Standardized protocol improves asthma management in emergency department
Christos Chouaid, Jean Pierre Bal, Claire Fuhrman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2026
Overcoming anti-PD-L1 resistance with anti-PD1 therapy: A case report and putative rationale
Karim Amrane, Coline LE Meur, Christos Chouaid, et al.
Bulletin Du Cancer
|
May 23, 2008
[Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule]
Isabelle Borget, Christos Chouaid, Nadia Demarteau, et al.
Lung
|
February 10, 2022
Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program
Virginie Avrillon, Catherine Daniel, Pierre Boisselier, et al.
The Clinical Respiratory Journal
|
October 14, 2014
Delays for diagnosis and treatment of lung cancers: a systematic review
Florent Vinas, Ikram Ben Hassen, Laurence Jabot, et al.
BMJ Supportive & Palliative Care
|
September 2, 2019
Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care
Olivier Bylicki, Morgane Didier, Frederic Riviere, et al.
Current Medical Research and Opinion
|
June 15, 2007
Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis
Christos Chouaid, Isabelle Monnet, Gilles Robinet, et al.
Bulletin Du Cancer
|
May 29, 2016
[Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database]
Gilles Freyer, Florian Scotte, Isabelle Borget, et al.
Page
of 21
Search research articles
Search
Showing results (21-30 of 209) with videos related to
Sort By:
Page
of 21
Current Oncology (Toronto, Ont.)
|
November 26, 2025
Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review
Hervé Bischoff, Sébastien Gendarme, Laura Somme, et al.
Journal of Medical Economics
|
December 2, 2024
The impact of <i>KRAS</i> mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany
Christos Chouaid, Andromachi Giannopoulou, Alexandra Starry, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
March 30, 2004
Standardized protocol improves asthma management in emergency department
Christos Chouaid, Jean Pierre Bal, Claire Fuhrman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2026
Overcoming anti-PD-L1 resistance with anti-PD1 therapy: A case report and putative rationale
Karim Amrane, Coline LE Meur, Christos Chouaid, et al.
Bulletin Du Cancer
|
May 23, 2008
[Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule]
Isabelle Borget, Christos Chouaid, Nadia Demarteau, et al.
Lung
|
February 10, 2022
Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program
Virginie Avrillon, Catherine Daniel, Pierre Boisselier, et al.
The Clinical Respiratory Journal
|
October 14, 2014
Delays for diagnosis and treatment of lung cancers: a systematic review
Florent Vinas, Ikram Ben Hassen, Laurence Jabot, et al.
BMJ Supportive & Palliative Care
|
September 2, 2019
Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care
Olivier Bylicki, Morgane Didier, Frederic Riviere, et al.
Current Medical Research and Opinion
|
June 15, 2007
Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis
Christos Chouaid, Isabelle Monnet, Gilles Robinet, et al.
Bulletin Du Cancer
|
May 29, 2016
[Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database]
Gilles Freyer, Florian Scotte, Isabelle Borget, et al.
Page
of 21